Beyond Dystonia: The Therapeutic Benefits of Botulinum Toxin Type A in Neurological Disorders
Neuropharmacology and Therapy · 2025
DOI: 10.15212/npt-2024-0014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropharmacology and Therapy, 2025. Verfasst von Yang Li und 4 weiteren Autor:innen. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BoNT type A (BoNT-A) is a neurotoxic protein produced by the anaerobic bacterium Clostridium botulinum . In recent years, BoNT-A has demonstrated substantial efficacy in the management of various diseases, particularly neurological disorders, and has served as a versatile therapeutic agent in modern medicine. This review is aimed at comprehensively examining the application of BoNT-A in various non-dystonia disorders—including hyperhidrosis, salivation, chronic migraine, trigeminal neuralgia, postherpetic neuralgia, primary tremor, depression, and Parkinson’s disease—in the field of neurology.
Zitieren
APA
Li, Y., Wei, W., Zhu, H., Tan, Y., & Luo, W. (2025). Beyond Dystonia: The Therapeutic Benefits of Botulinum Toxin Type A in Neurological Disorders. Neuropharmacology and Therapy. https://doi.org/10.15212/npt-2024-0014
Vancouver
Li Y, Wei W, Zhu H, Tan Y, Luo W. Beyond Dystonia: The Therapeutic Benefits of Botulinum Toxin Type A in Neurological Disorders. Neuropharmacology and Therapy. 2025. doi:10.15212/npt-2024-0014
BibTeX
@article{Li2025,
author = {Li, Yang and Wei, Wei and Zhu, Hanyu and Tan, Ying and Luo, Weifeng},
title = {Beyond Dystonia: The Therapeutic Benefits of Botulinum Toxin Type A in Neurological Disorders},
journal = {Neuropharmacology and Therapy},
year = {2025},
doi = {10.15212/npt-2024-0014}
}
EUVIMED